Drug updated on 4/18/2024
| Dosage Form | Injection (intravenous; 25 mg/1.25 mL (20 mg/mL), 300 mg/15 mL (20 mg/mL)) |
| Drug Class | Cytotoxic T-lymphocyte antigen 4-blocking antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) in combination with durvalumab.
- Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations in combination with durvalumab and platinum-based chemotherapy.
Summary
- Imjudo (tremelimumab) is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) and metastatic non-small cell lung cancer (NSCLC), in combination with durvalumab and platinum-based chemotherapy. It has demonstrated statistically significant survival benefits, improved response rates, and progression-free survival over old standards like sorafenib.
- Three studies provided information on the use of Imjudo in combination therapies for uHCC and NSCLC.
- The combination of tremelimumab with durvalumab shows a safety profile with predictable adverse events that are manageable across different treatment lines, implying a balance between efficacy and safety compared to drugs such as sorafenib.
- For advanced HCC, the combination of tremelimumab and durvalumab marks an improvement over older therapies like sorafenib. However, for extensive-stage small cell lung cancer, serplulimab combined with chemotherapy has been identified as preferable based on overall survival data.
- No significant differences were found in the frequency of adverse events between first-line treatments or later stages, indicating consistency in safety across various cancers treated by this combination therapy.
- Although subgroup analyses were not extensively detailed, the findings suggest potential broad applicability across different lines of treatment, possibly extending to various types of cancer beyond those specified.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Imjudo (tremelimumab) Prescribing Information. | 2023 | AstraZeneca Pharmaceuticals LP, Wilmington, DE |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review. | 2023 | Cancer Treatment Reviews |
| Adverse events induced by durvalumab and tremelimumab combination regimens: A systematic review and meta-analysis. | 2023 | Therapeutic advances in medical oncology |
| Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: A Bayesian network meta-analysis. | 2023 | Frontiers in Immunology |